CKS1B Human Pre-designed siRNA Set A

Cat. No.: C1488872
Disponible para pedir
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
★
Talla
Alemania (EU)
USA*
Precio
Cantidad
1Set
C1488872-1Set
Fabricado bajo pedido · 8–12 semanas
261,10€
Enter a quantity for the sizes you want to add.

Descripción general

CKS1B Human Pre-designed siRNA Set A contains three designed siRNAs for CKS1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components CKS1B siRNA-1: 5 nmol (HPLC) CKS1B siRNA-2: 5 nmol (HPLC) CKS1B siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Especificaciones

Condiciones de almacenamiento de almacenamiento
Store at -20°C
Enviado en
Ice chest + Ice pads
Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.
Product Line
Productos biológicos

Datos avanzados

Certificados (CoA, COO, BSE/TSE y tabla de análisis)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calculadoras de soluciones
Reseñas

Reseñas de cliente

Application Protocols

No item‑specific, vendor‑validated application protocols are provided in the product data. The following is general guidance for siRNA transfection (literature/general):

  • Preparation:
    • Thaw on ice; briefly spin. Reconstitute each duplex in RNase‑free water or TE‑Low to 20–100 µM. Aliquot to avoid freeze–thaw.
  • Complexing (example workflow):
    • Dilute siRNA in nuclease‑free water or serum‑reduced medium to 2× the desired final concentration.
    • Dilute transfection reagent separately as per manufacturer’s instructions.
    • Combine equal volumes; incubate 10–20 min at room temperature to form complexes.
  • Transfection:
    • Replace culture medium with fresh complete medium (antibiotic‑free if recommended).
    • Add complexes dropwise to cells (target final siRNA 1–50 nM).
    • Gently rock plate to distribute; incubate 24–72 h.
  • Assessment:
    • RT‑qPCR for CKS1B mRNA at 24–48 h; immunoblot for protein at 48–96 h.
    • Include non‑targeting and positive control siRNAs; normalize to housekeeping genes.

Consult your transfection reagent’s protocol for reagent‑specific volumes and conditions. For item‑specific instructions, sequences, and controls, refer to the CoA/Spec Sheet.

Biological Roles

Target gene context (literature/general): CKS1B (CDC28 protein kinase regulatory subunit 1B) encodes a small acidic protein that binds cyclin‑dependent kinases (CDKs) and functions as an adaptor within the SCFSkp2 E3 ubiquitin ligase complex.

  • Functional highlights:
    • Facilitates Skp2‑dependent recognition/ubiquitination of CDK inhibitors such as p27Kip1, thereby promoting their proteasomal degradation and influencing G1/S transition
    • Interacts with CDK1/2 and cyclins to modulate kinase activity and substrate selection in cell cycle progression
    • Implicated in regulation of DNA replication licensing and checkpoint responses through CDK substrate turnover
  • Pathway placement: Cell cycle control, ubiquitin‑proteasome system, and CDK signaling networks
  • Cellular localization: Predominantly nuclear with cell cycle‑regulated distribution (varies by cell type; literature/general)
  • Experimental implications for RNAi:
    • Knockdown of CKS1B typically stabilizes p27 and related CDK inhibitors, reducing S‑phase entry; phenotypic outcomes depend on cell context
    • Useful for dissecting SCFSkp2 substrate processing, CDK activity thresholds, and proliferation control

Note: The above roles are general literature context for the gene target. The product itself is for research use only and is not intended for diagnostic or therapeutic applications.

Buffer Applications

This product is not a buffering agent. However, successful siRNA handling depends on selecting appropriate RNase‑free buffers (literature/general):

  • Reconstitution/storage buffers:
    • RNase‑free water for short‑term use
    • TE‑Low: 10 mM Tris‑HCl, pH 7.5–8.0 with 0.1–1.0 mM EDTA for enhanced stability during long‑term storage
  • Working solutions for transfection:
    • Dilute siRNA in nuclease‑free water or serum‑reduced medium (e.g., Opti‑MEM) immediately before complex formation per transfection reagent instructions
    • Avoid high‑salt phosphate buffers during complexation as they can screen electrostatic interactions with cationic lipids/polymers
  • RNase control:
    • Use certified RNase‑free consumables
    • Wipe benches/equipment with RNase decontamination solutions

Recipes (example, general):

  • 10 mM Tris‑HCl, pH 7.5: 1.21 g Tris base per liter; adjust pH with HCl; optionally add 0.1–1.0 mM EDTA; filter sterilize and store at 4°C.

Item‑specific buffer requirements are not specified; refer to the CoA/Spec Sheet and your transfection reagent protocol.

Green Alternatives

Although this product is an aqueous nucleic acid reagent, greener practices can reduce environmental impact in RNAi workflows.

  • Prefer aqueous systems: Prepare and store siRNA in RNase‑free water or TE‑Low instead of organic cosolvents (general).
  • Reduce single‑use plastics: Where compatible with RNase‑free technique, employ certified RNase‑free reusable racks and minimize tube/tip waste (general).
  • Energy considerations: Consolidate freezer space; store working aliquots at −20°C and archival stocks at −80°C only if required (general).
  • Safer transfection reagents: Consider biodegradable/low‑toxicity lipid or polymer systems to reduce hazardous waste compared to older cationic surfactants (general).
  • Waste management: Aqueous siRNA solutions are typically non‑hazardous; segregate biological waste from organic solvent waste streams and avoid chlorinated solvent use (general).

Comparison (general):

  • Plasmid/shRNA systems: Lower reagent waste per experiment but require bacterial culture, antibiotics, and DNA extraction (higher resource use, biohazard waste).
  • Synthetic siRNA: No microbial amplification, minimal solvent use, faster turnaround; packaging waste from single‑use consumables is the main footprint.

For this specific item, no alternative green formulation is specified; refer to CoA/Spec Sheet for any stabilization additives or recommended diluents.

Pharmaceutical Uses

This product is supplied strictly for research use only. No pharmacopeial status, excipient role, or clinical use is provided or implied.

  • Regulatory status: Research use only; not for human or veterinary use.
  • Formulation context (general): Laboratory siRNA duplexes are commonly formulated in RNase‑free aqueous buffers for in vitro cell culture studies. Any clinical formulation aspects (e.g., LNPs, conjugates) are outside the scope of this product and not specified.

For any application beyond basic research (e.g., preclinical development), consult appropriate regulatory guidance and source materials manufactured under suitable quality systems. Item‑specific pharmaceutical specifications are not provided for this product.

Physical Properties

Item-specific physicochemical specifications (e.g., MW, extinction coefficients) are sequence‑dependent and not provided.

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet. (Each duplex MW varies with sequence/length.)
  • Solubility (literature/general):
    • Freely soluble in nuclease‑free water and aqueous buffers (e.g., 10 mM Tris, pH 7.5–8.0) at ≥100 µM
    • Insoluble in most nonpolar organic solvents
  • pKa / logP: Not applicable to polyanionic oligoribonucleotides; behaves as a highly charged hydrophilic biopolymer (literature/general)
  • UV absorbance (literature/general): Strong absorbance at 260 nm; strand‑specific ε260 is sequence‑dependent. Concentration often determined by A260 using sequence‑calculated extinction coefficients.
  • Thermal behavior (literature/general): Duplexes exhibit a melting temperature (Tm) that depends on sequence, length, salt conditions, and chemical modifications; typical siRNA Tm is well above ambient in physiological salt.
  • Density/refractive index/boiling point/melting point: Not applicable/Not typically defined for oligonucleotide solutions; Not specified for this item; refer to CoA/Spec Sheet.

Practical note (general): Reconstitute in RNase‑free water or buffer; avoid divalent cations >1 mM unless required, as they can promote degradation in the presence of nucleases.

Quality and Grades
  • Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
  • What “Pre‑designed siRNA Set A” typically signifies (literature/general):
    • Multiple non‑overlapping duplexes targeting distinct regions of the human CKS1B mRNA to enable rapid knockdown screening and to mitigate off‑target risk via pooled or sequential use.
    • In‑silico design against current RefSeq/Ensembl transcripts with filters for low off‑target seed matches and appropriate GC content.
    • Each duplex typically supplied desalted or further purified (e.g., HPLC) depending on vendor specification; purification level for this item is not specified.
  • QC considerations for siRNA (general):
    • Identity: Mass confirmation by ESI‑MS/MALDI (sequence‑dependent); Not specified for this item.
    • Purity: Crude/desalted vs. HPLC grade affects performance and off‑target effects; Not specified for this item.
    • Duplexing: Annealing/duplex content can be verified by non‑denaturing PAGE or ion‑pair HPLC; Not specified for this item.
    • Functional QC: Knockdown efficiency in a reference cell line and absence of immunostimulation can be evaluated; Not specified for this item.

Refer to the CoA/Spec Sheet for the definitive grade, purification method, and any functional validation specific to SKU C1488872.

Reaction and Applications

As a pre‑designed siRNA set against human CKS1B, this product is intended for RNA interference (RNAi) experiments in mammalian cells (research use only).

  • Principal application (general): Sequence‑specific post‑transcriptional gene silencing via RISC‑mediated cleavage of CKS1B mRNA.
  • Use cases (general):
    • Rapid target validation and loss‑of‑function phenotyping in human cell lines
    • Pathway dissection involving SCFSkp2–p27 regulatory axes where CKS1B participates
    • Positive/negative control benchmarking of transfection conditions (with appropriate non‑targeting and housekeeping controls)
  • Practical tips (general):
    • Optimize transfection reagent, cell density (30–60% confluence for adherent cells), and siRNA dose (typically 1–50 nM depending on cell line/reagent)
    • Start with pooled use of the set to maximize knockdown, then deconvolute to single duplexes to confirm on‑target effects
    • Assess mRNA knockdown by RT‑qPCR at 24–48 h; assess protein reduction by immunoblot at 48–96 h (turnover‑dependent)
    • Minimize off‑targeting by limiting final concentration and avoiding seed‑mediated effects (use independent duplexes and rescue experiments)
  • Controls (general): Non‑targeting siRNA, siRNA targeting an unrelated gene, and a known on‑target rescue (cDNA lacking 3′UTR) where applicable.

Note: Specific sequences, recommended working concentrations, and any vendor‑validated applications are not specified for this item; consult the CoA/Spec Sheet for item‑specific guidance.

Reaction Conditions

While not a chemical reaction reagent, siRNA transfection has configurable “conditions” that determine knockdown efficiency (literature/general):

  • Cell seeding: Plate adherent cells to 30–60% confluence at transfection time to balance viability and uptake.
  • siRNA dose: Typical final concentrations 1–50 nM; begin with 10 nM and titrate down to minimize off‑targets while maintaining efficacy. Some cell types respond at 1–5 nM.
  • Complex formation: Dilute siRNA and transfection reagent separately in serum‑reduced medium or water, combine at vendor‑recommended ratios, incubate 10–30 min to allow complexation.
  • Incubation: Add complexes dropwise; incubate 4–6 h before media refresh if reagent requires, or leave in complete medium for no‑change protocols.
  • Readouts: mRNA knockdown at 24–48 h; protein knockdown at 48–96 h depending on protein half‑life.
  • Controls: Non‑targeting control, mock (reagent only), and positive control siRNA.

Item‑specific optimal conditions (exact concentration, reagent type, exposure time) are not specified for this product and should be optimized empirically for each cell line and transfection system.

Safety and Handling

Safety classifications specific to this item have not been provided. Handle as a laboratory nucleic acid reagent.

  • GHS classification: Not specified for this item; refer to SDS.
  • Signal word / H‑statements / Pictograms: Not specified for this item; refer to SDS.
  • Primary hazards (literature/general): Low acute toxicity expected for short oligonucleotides; main risks are dust/aerosol inhalation and potential skin/eye irritation. Avoid generating aerosols. Treat as non‑sterile, non‑pyrogenic research reagent.
  • PPE: Laboratory coat, nitrile gloves, and safety glasses. Use RNase‑free technique (dedicated gloves/tubes/tips) to prevent sample degradation.
  • Handling: Work on clean, RNase‑free surfaces; change gloves frequently; keep tubes closed to prevent aerosol contamination. Use biological safety cabinet if handling large numbers of cell cultures.
  • Incompatibilities (general): Strong oxidizers, nucleases (RNase contamination). Avoid repeated freeze–thaw; avoid high temperatures (>65°C) unless purposefully deannealing.
  • First aid (general):
    • Inhalation: Move to fresh air; seek medical attention if symptoms persist.
    • Skin/eye contact: Rinse with water for several minutes; remove contaminated clothing; seek medical advice if irritation persists.
    • Ingestion: Rinse mouth; do not induce vomiting; seek medical attention as appropriate.

Always consult the product’s SDS for authoritative safety and regulatory information. For research use only.

Solvent Selection

This product is an RNA duplex reagent; conventional organic solvent selection is not applicable. Focus on RNase‑free aqueous systems.

  • Primary diluents (literature/general):
    • RNase‑free water (ultrapure)
    • 10 mM Tris‑HCl, pH 7.5–8.0; 0.1–1 mM EDTA ("TE" or "TE‑Low") for enhanced stability against adventitious divalent cations
    • HEPES, pH 7.2–7.6 (cell‑friendly buffering when preparing transfection mixes)
  • Compatibility with transfection (general): Maintain low ionic strength in complexation step with cationic lipids/polymers; many reagents recommend diluting siRNA in nuclease‑free water or Opti‑MEM/serum‑reduced media prior to complexing.
  • Avoid (general):
    • Solvents containing RNases or high concentrations of divalent cations (Mg2+, Ca2+) unless required
    • Strongly acidic/basic buffers that can promote hydrolysis
  • Quick comparison (general):
    • Water: maximal compatibility, simplest; lowest buffering capacity
    • TE/TE‑Low: improved long‑term stability; EDTA may chelate cationic transfection reagents—dilute prior to complexing
    • HEPES‑buffered saline: suitable for cell handling steps but typically not for complex formation

Choose solvent based on the immediate application: storage (TE‑Low), complex preparation (water or serum‑reduced medium), and cell culture delivery (complete medium post‑complexing).

Storage and Reconstitution
  • Storage conditions (item‑specific): Store at −20°C. Shipped in an ice chest with ice pads.
  • Long‑term storage (general): For maximum stability, store lyophilized siRNA desiccated at −20 to −80°C. Store aqueous aliquots at −20°C (short‑to‑mid term) or −80°C (long term). Protect from repeated freeze–thaw.
  • Reconstitution (general):
    • Use RNase‑free water or TE‑Low (10 mM Tris‑HCl, pH 7.5–8.0; 0.1–1.0 mM EDTA).
    • Target stock concentration: 20–100 µM; vortex gently and spin down; allow 10 min at room temperature for complete dissolution.
    • If provided single‑stranded, anneal equimolar strands by heating to 90°C for 1–2 min and cooling slowly to room temperature; duplex status for this item is not specified.
  • Aliquoting (general): Prepare small, single‑use aliquots to avoid freeze–thaw cycles; label with sequence ID, concentration, and date.
  • Handling: Maintain RNase‑free technique; keep on ice during setup.

Item‑specific details such as exact formulation, residual solvents, quantity per vial, and duplex/annealing status are not specified for this product; refer to the CoA/Spec Sheet.

Structure and Identity

This product is a pre-designed small interfering RNA (siRNA) set targeting human CKS1B (CDC28 protein kinase regulatory subunit 1B) transcripts.

  • SKU: C1488872
  • Product name: CKS1B Human Pre-designed siRNA Set A
  • Intended target: Human CKS1B mRNA (gene symbol: CKS1B)
  • Composition: Mixture/set of synthetic double‑stranded RNA duplexes (sense/antisense), typically 19–21 bp with 2‑nt 3′ overhangs (literature/general)
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet. (Sequence‑dependent for each duplex)
  • SMILES / InChI / InChIKey: Not applicable to mixed oligonucleotide duplexes; not specified for this item; refer to CoA/Spec Sheet.
  • Structural features (literature/general):
    • Double‑stranded RNA helix in A‑form geometry under physiological ionic strength
    • 5′ phosphate or hydroxyl termini depending on synthesis; 3′ two‑nucleotide overhangs (often dTdT) to enhance RISC loading
    • May include optional stabilizing modifications (e.g., 2′‑OMe, phosphorothioate) depending on design; not specified for this item
  • 2D description: Each duplex comprises a sense strand complementary to target mRNA and an antisense (guide) strand that is incorporated into RISC to direct sequence‑specific cleavage (literature/general).

Note: Exact sequences, lengths, modifications, and strand stoichiometry are not provided here; consult the item’s CoA/Spec Sheet for definitive identity details.

Synthetic Utility

Not a chemical building block for synthetic organic transformations. As a functional oligonucleotide reagent, its “utility” is in targeted gene silencing in cells (literature/general):

  • Experimental utility:
    • Programmable, sequence‑defined suppression of CKS1B expression to support mechanism studies and target validation
    • Tool for establishing causal links between CKS1B levels and downstream phenotypes (e.g., p27 accumulation, cell cycle changes)
  • Complementary approaches:
    • Use alongside CRISPRi/CRISPR knockout to compare acute vs. permanent loss‑of‑function
    • Combine with overexpression/rescue constructs lacking siRNA binding sites to demonstrate on‑target effects

No synthetic chemistry transformations, named reactions, or building‑block roles apply to this product.

Target Specificity

Information in this section is limited to product data only.

  • Target gene: CKS1B
  • Species reactivity: Human (as stated in product name)
  • Set designation: Pre‑designed siRNA Set A
  • Sequence information: Not specified for this item; refer to CoA/Spec Sheet.
  • Validated transcripts/isoforms, off‑target analysis, and cross‑reactivity: Not specified for this item; refer to CoA/Spec Sheet.

No additional specificity data are provided in the product data.

¿Quieres que te enviemos un mensaje cuando tengamos descuentos disponibles?

Recordármelo más tarde

¡Gracias! Por favor, revisa tu bandeja de entrada de correo electrónico para confirmar.

¡Vaya! Las notificaciones están desactivadas.